AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27251517 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TXA) administered under endoscopic therapy
Number of subjects: 63
Study 27251517 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine (1/10,000) submucosally injected to ulcer margins
Number of subjects: 63
Study 25248949 — intervention group
Group type: EXPERIMENTAL
Intervention: PBE with feldspathic ceramic (G1)
Number of subjects: 48
Study 25248949 — intervention group
Group type: EXPERIMENTAL
Intervention: PBE with resin nano-ceramic (G2)
Number of subjects: 48
Study 25248949 — intervention group
Group type: COMPARATOR
Intervention: No PBE with feldspathic ceramic (G3)
Number of subjects: 48
Study 25248949 — intervention group
Group type: COMPARATOR
Intervention: No PBE with resin nano-ceramic (G4)
Number of subjects: 48
Study 23525983 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sitafloxacin once daily (100 mg qd group)
Number of subjects: 90
Study 23525983 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sitafloxacin twice daily (50 mg bid group)
Number of subjects: 90
Study 23525983 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 90
Study 20637457 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible GnRH antagonist administration (started when LH >10 IU/L, or follicle >12 mm, or serum E(2) >150 pg/mL)
Number of subjects: 146
Study 20637457 — intervention group
Group type: COMPARATOR
Intervention: Fixed GnRH antagonist administration (started on day 6 of stimulation)
Number of subjects: 146
Study 18946456 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6)
Number of subjects: 45
Study 18946456 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 45
Study 16499576 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal vaccine delivery (OptiMist device, nasal drops)
Number of subjects: 65
Study 16499576 — intervention group
Group type: COMPARATOR
Intervention: Oral spray immunization
Number of subjects: 65
Study 14584553 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired ability to retrieve events from the anterograde period
Number of subjects: 1
Study 14584553 — intervention group
Group type: EXPERIMENTAL
Intervention: Spared ability to retrieve events from the retrograde period
Number of subjects: 1
Study 14584553 — intervention group
Group type: EXPERIMENTAL
Intervention: n-back task performance
Number of subjects: 1
Study 14584553 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic recognition memory task
Number of subjects: 1
Study 10478148 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary zone electrophoresis (CZE)
Number of subjects: 695
Study 10478148 — intervention group
Group type: COMPARATOR
Intervention: Agarose gel electrophoresis (AGE)
Number of subjects: 695
Study 10478148 — intervention group
Group type: EXPERIMENTAL
Intervention: Immuno-subtraction electrophoresis (ISE)
Number of subjects: 695
Study 10478148 — intervention group
Group type: COMPARATOR
Intervention: Immunofixation electrophoresis (IFE)
Number of subjects: 695
Study 8917826 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier cream formulation 1
Number of subjects: 6
Study 8917826 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier cream formulation 2
Number of subjects: 6
Study 8917826 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier cream formulation 3
Number of subjects: 6
Study 1760699 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal surgery (under‐running the vessel or ulcer excision and adjuvant ranitidine)
Number of subjects: 137
Study 1760699 — intervention group
Group type: COMPARATOR
Intervention: Conventional ulcer surgery (vagotomy and pyloroplasty or partial gastrectomy)
Number of subjects: 137
Study 6981593 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoretic application of Placenta‐Lucchini in combination with catalase and mucopolysaccharidase
Number of subjects: 0
Study 6981593 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra‐articular application of Placenta
Number of subjects: 0
Study 31573855 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-tissue gas identified on postoperative radiography after TKA
Number of subjects: 204
Study 31573855 — intervention group
Group type: COMPARATOR
Intervention: No soft-tissue gas identified on postoperative radiography after TKA
Number of subjects: 204
Study 31573855 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of soft-tissue gas on radiography 14 days after TKA
Number of subjects: 204
Study 31573855 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-tissue gas cases
Number of subjects: 204
Study 28210935 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid resuscitation (15 ml kg‐1 fluid in 30 min)
Number of subjects: 30
Study 27804268 — intervention group
Group type: EXPERIMENTAL
Intervention: Canola oil diet
Number of subjects: 101
Study 27804268 — intervention group
Group type: EXPERIMENTAL
Intervention: CanolaOleic oil diet
Number of subjects: 101
Study 27804268 — intervention group
Group type: COMPARATOR
Intervention: Flax/Safflower oil diet
Number of subjects: 101
Study 24590751 — intervention group
Group type: EXPERIMENTAL
Intervention: Information explaining the lack of evidence that MMR causes autism from the CDC
Number of subjects: 1759
Study 24590751 — intervention group
Group type: EXPERIMENTAL
Intervention: Textual information about the dangers of the diseases prevented by MMR from the Vaccine Information Statement
Number of subjects: 1759
Study 24590751 — intervention group
Group type: EXPERIMENTAL
Intervention: Images of children who have diseases prevented by the MMR vaccine
Number of subjects: 1759
Study 24590751 — intervention group
Group type: EXPERIMENTAL
Intervention: A dramatic narrative about an infant who almost died of measles from a CDC fact sheet
Number of subjects: 1759
Study 24590751 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1759
Study 22903248 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumoperitoneum (IPP)
Number of subjects: 26
Study 22903248 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon's perception of breaks
Number of subjects: 26
Study 20423424 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-day embedded academic learning support workshop
Number of subjects: 106
Study 20423424 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 106
Study 18690343 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombin generation measurement using Calibrated Automated Thrombogram (CAT)
Number of subjects: 104
Study 18690343 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombin generation measurement with thrombomodulin
Number of subjects: 104
Study 18690343 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of protein C activity, protein S antigen, and free protein S with ETP
Number of subjects: 104
Study 18690343 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of FVIII levels and thrombomodulin induced reduction of ETP and peak height
Number of subjects: 104
Study 16219122 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 16219122 — intervention group
Group type: COMPARATOR
Intervention: Medications alone
Number of subjects: 0
Study 12211508 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary weight loss and exercise
Number of subjects: 316
Study 12211508 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary weight loss
Number of subjects: 316
Study 12211508 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 316
Study 12211508 — intervention group
Group type: COMPARATOR
Intervention: Healthy lifestyle control
Number of subjects: 316
Study 10519936 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib-tetanus toxoid conjugate vaccine (Hib-T)
Number of subjects: 287
Study 10519936 — intervention group
Group type: EXPERIMENTAL
Intervention: DT- IPV mixed vaccine
Number of subjects: 287
Study 10519936 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous administration
Number of subjects: 287
Study 10519936 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanus toxoid (T) as a carrier protein
Number of subjects: 287
Study 8821074 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 0
Study 8821074 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 2074087 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH(1-29)NH2, 1 microgram/kg
Number of subjects: 76
Study 2074087 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH(1-44)NH2, 1 and 2 microgram/kg administered in random order
Number of subjects: 76
Study 2074087 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH tests performed on 2 consecutive days
Number of subjects: 76
Study 6947118 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent combination chemotherapy at 4-week intervals
Number of subjects: 136
Study 6947118 — intervention group
Group type: COMPARATOR
Intervention: Specific immunotherapy with neuraminidase-modified allogeneic blast cells
Number of subjects: 136
Study 6418549 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g mezlocillin single-dose prophylaxis given immediately before surgery
Number of subjects: 358
Study 6418549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 358
Study 6418549 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g mezlocillin single-dose prophylaxis
Number of subjects: 358
Study 29361442 — intervention group
Group type: COMPARATOR
Intervention: tDCS at 0.034 mA
Number of subjects: 100
Study 29361442 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS at 1 mA
Number of subjects: 100
Study 29361442 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS at 2 mA
Number of subjects: 100
Study 29361442 — intervention group
Group type: COMPARATOR
Intervention: tDCS at 0.016 mA
Number of subjects: 100
Study 29361442 — intervention group
Group type: COMPARATOR
Intervention: tDCS at 0 mA
Number of subjects: 100
Study 28157084 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage (15 minutes, twice a week for 4 weeks, total of 8 sessions)
Number of subjects: 50
Study 28157084 — intervention group
Group type: COMPARATOR
Intervention: Control group (no massage)
Number of subjects: 50
Study 24770625 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 24
Study 24770625 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-649868
Number of subjects: 24
Study 24770625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 23175341 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole, 200 mg daily for six weeks
Number of subjects: 36
Study 23175341 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 participants without clinical disorders)
Number of subjects: 36
Study 23175341 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole treatment
Number of subjects: 36
Study 20021706 — intervention group
Group type: EXPERIMENTAL
Intervention: Salient shared humanity with a benevolent human norm
Number of subjects: 186
Study 20021706 — intervention group
Group type: COMPARATOR
Intervention: Salient shared humanity with a hostile human norm
Number of subjects: 186
Study 20021706 — intervention group
Group type: EXPERIMENTAL
Intervention: Salient shared humanity with a hostile human norm (when perpetrator intentions were unambiguously negative)
Number of subjects: 186
Study 20021706 — intervention group
Group type: EXPERIMENTAL
Intervention: Salient shared humanity with a hostile human norm (when perpetrator intentions were ambiguous)
Number of subjects: 186
Study 18606033 — intervention group
Group type: EXPERIMENTAL
Intervention: Head Start REDI intervention
Number of subjects: 356
Study 18606033 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial EF
Number of subjects: 356
Study 15787675 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg)
Number of subjects: 10
Study 15787675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11916372 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium (Depakote) detoxification
Number of subjects: 16
Study 11916372 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium (Depakote) detox plus maintenance
Number of subjects: 16
Study 11916372 — intervention group
Group type: COMPARATOR
Intervention: Standard benzodiazepine detoxification
Number of subjects: 16
Study 10610014 — intervention group
Group type: EXPERIMENTAL
Intervention: Olestra group (1.5 servings/day of Pringles with olestra for 2 weeks)
Number of subjects: 40
Study 10610014 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (1.5 servings/day of Pringles without olestra for 2 weeks)
Number of subjects: 40
Study 10610014 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 7793192 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular morphine-scopolamine (0.15 +/- 0.006 mg x kg-1)
Number of subjects: 205
Study 7793192 — intervention group
Group type: COMPARATOR
Intervention: Rectal hydrogel of morphine-scopolamine (0.25 +/- 0.015 mg x kg-1)
Number of subjects: 205
Study 1846876 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate diet
Number of subjects: 8
Study 1846876 — intervention group
Group type: COMPARATOR
Intervention: High fat diet
Number of subjects: 8
Study 7320363 — intervention group
Group type: EXPERIMENTAL
Intervention: Modularized stress reduction packet
Number of subjects: 299
Study 7320363 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 299
Study 31481364 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised Risk Report embedded in the electronic health record, printed with auto‐filled results, used as a discussion aid during the NHS Health Check.
Number of subjects: 18
Study 31481364 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised Risk Report
Number of subjects: 18
Study 28316118 — intervention group
Group type: EXPERIMENTAL
Intervention: Late preterm infants
Number of subjects: 118
Study 28316118 — intervention group
Group type: COMPARATOR
Intervention: Full-term infants
Number of subjects: 118
Study 25597457 — intervention group
Group type: COMPARATOR
Intervention: Trained control group (TDT)
Number of subjects: 39
Study 25597457 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained study group (SSDT)
Number of subjects: 39
Study 25597457 — intervention group
Group type: COMPARATOR
Intervention: Nontrained groups (TDNT and SSDNT)
Number of subjects: 39
Study 25597457 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 39
Study 23463483 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.9 mg · kg(‐1)
Number of subjects: 16
Study 20848578 — intervention group
Group type: EXPERIMENTAL
Intervention: Laughter Yoga
Number of subjects: 70
Study 20848578 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Exercise Therapy
Number of subjects: 70
Study 20848578 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 70
Study 18796139 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxane-based chemotherapy
Number of subjects: 4500
Study 16942980 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing
Number of subjects: 0
Study 16942980 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 12641635 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg progesterone intramuscularly (i.m.)
Number of subjects: 20
Study 12641635 — intervention group
Group type: COMPARATOR
Intervention: 300 micro g desogestrel orally daily for 7 days
Number of subjects: 20
Study 11300427 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 37
Study 11300427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 9262495 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1 g per day) during lactation
Number of subjects: 383
Study 9262495 — intervention group
Group type: COMPARATOR
Intervention: Placebo during lactation
Number of subjects: 383
Study 9262495 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1 g per day) after weaning
Number of subjects: 383
Study 9262495 — intervention group
Group type: COMPARATOR
Intervention: Placebo after weaning
Number of subjects: 383
Study 9262495 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1 g per day)
Number of subjects: 383
Study 8120154 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 50
Study 8120154 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin
Number of subjects: 50
Study 8120154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 3632762 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (1.5 g oil/10 kg b.wt./day for three weeks)
Number of subjects: 21
Study 3632762 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (1.5 g oil/10 kg b.wt./day for three weeks)
Number of subjects: 21
Study 29559294 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 121
Study 29559294 — intervention group
Group type: EXPERIMENTAL
Intervention: External cold and vibration
Number of subjects: 121
Study 29559294 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 121
Study 28347292 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 2 mg
Number of subjects: 0
Study 28347292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26185909 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 1.5 to 2.5 mg/kg/day
Number of subjects: 26
Study 26185909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 26185909 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (for nonresponders switched from placebo)
Number of subjects: 26
Study 26185909 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 26
Study 23306448 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS(a) + AT
Number of subjects: 18
Study 23306448 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS(c) + AT
Number of subjects: 18
Study 21040412 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-I treatment (50 μg/kg, twice daily for 7 days)
Number of subjects: 16
Study 21040412 — intervention group
Group type: COMPARATOR
Intervention: Control (saline injections)
Number of subjects: 16
Study 18976450 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A (docetaxel 70 mg/m2 on day 1 and gemcitabine 900 mg/m2 on days 3-8, every 3 weeks)
Number of subjects: 0
Study 18976450 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B (gemcitabine 900 mg/m2 on days 1 and 8, and docetaxel 70 mg/m2 on day 8, every 3 weeks)
Number of subjects: 0
Study 17002625 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT FFP
Number of subjects: 35
Study 17002625 — intervention group
Group type: COMPARATOR
Intervention: Control FFP
Number of subjects: 35
Study 14601230 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyalofill-F plus compression bandaging
Number of subjects: 20
Study 11113492 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin treatment (0.3 mg administered 3.5 h after nicotine withdrawal)
Number of subjects: 0
Study 11113492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8730247 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-H. pylori treatment with different drugs
Number of subjects: 182
Study 8730247 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without electron microscopic features of infiltration
Number of subjects: 182
Study 8730247 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with bacteria deeply embedded into the gastric mucosa
Number of subjects: 182
Study 8730247 — intervention group
Group type: COMPARATOR
Intervention: No specific treatment
Number of subjects: 182
Study 1305469 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuated strain of influenza A virus
Number of subjects: 0
Study 1305469 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 3891357 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF + tamoxifen (T)
Number of subjects: 263
Study 3891357 — intervention group
Group type: COMPARATOR
Intervention: CMF
Number of subjects: 263
Study 31118740 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (six 2-hr group sessions over 6 months)
Number of subjects: 443
Study 31118740 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 443
Study 29252110 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet use
Number of subjects: 592
Study 29252110 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet access frequency
Number of subjects: 592
Study 29252110 — intervention group
Group type: EXPERIMENTAL
Intervention: Device used for Internet access
Number of subjects: 592
Study 29252110 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to use videoconferencing
Number of subjects: 592
Study 29252110 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfort with new devices (with in-person assistance)
Number of subjects: 592
Study 29252110 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfort with new devices (on your own)
Number of subjects: 592
Study 29252110 — intervention group
Group type: EXPERIMENTAL
Intervention: Association between Internet use and comfort with new technology devices
Number of subjects: 592
Study 27632268 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-microtextured implants
Number of subjects: 17
Study 27632268 — intervention group
Group type: COMPARATOR
Intervention: Machined implants
Number of subjects: 17
Study 25371457 — intervention group
Group type: EXPERIMENTAL
Intervention: 28 mm ceramic articulation
Number of subjects: 120
Study 25371457 — intervention group
Group type: COMPARATOR
Intervention: 32 mm ceramic articulation
Number of subjects: 120
Study 23101262 — intervention group
Group type: EXPERIMENTAL
Intervention: Liniment cycloferon included in combined therapy
Number of subjects: 30
Study 20486273 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril-indapamide
Number of subjects: 11140
Study 20486273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11140
Study 18588706 — intervention group
Group type: EXPERIMENTAL
Intervention: Community, school, and family-based intervention
Number of subjects: 0
Study 18588706 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 schools)
Number of subjects: 0
Study 15807808 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneometer CM-A (CM820)
Number of subjects: 53